Research Papers:

The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China

Xuhui Ma, Yunteng Wu, Tian Zhang, Hao Song, Houyu Jv, Wei Guo _ and Guoxin Ren

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:82661-82673. https://doi.org/10.18632/oncotarget.19746

Metrics: PDF 1488 views  |   HTML 2375 views  |   ?  


Xuhui Ma1,*, Yunteng Wu1,*, Tian Zhang1, Hao Song1, Houyu Jv1, Wei Guo1 and Guoxin Ren1

1Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200011, China

*These authors have contributed equally to this work

Correspondence to:

Wei Guo, email: [email protected]

Guoxin Ren, email: [email protected]

Keywords: oral mucosal melanomas, distal metastasis, c-Kit, c-Kit mutation, imatinib

Abbreviations: OMMs, oral mucosal melanomas; OS, overall survival; CLN, cervical lymph node; ECOG, Eastern Cooperative Oncology Group.

Received: March 13, 2017     Accepted: June 20, 2017     Published: July 31, 2017


c-Kit mutations are frequently detected in mucosal melanomas, but their clinical significance in metastatic oral mucosal melanomas (OMM) remains unclear. The main purpose of this study was to investigate the clinical and pathological features of metastatic OMMs with c-Kit mutations and the efficiency of the tyrosine kinase inhibitor imatinib in treating metastatic OMMs. We found thatresidual primary lesion and neck lymph nodes could act as independent prognostic factors in metastatic OMM patients. c-Kit mutations were detected in 22 out of 139 (15.8%) metastatic OMM patients. Under chemotherapy, the overall survival (OS) of c-Kit mutant patients was significantly shorter than that of wild-type patients. The Ki67 expression was significantly higher in c-Kit mutant patients than in wild-type patients. In distant metastatic OMM patients with c-Kit mutations, the treatment with c-Kit inhibitor resulted in a better OS. In conclusion, residual primary lesion, cervical lymph nodes and c-Kit mutations act as adverse prognostic factors of metastatic OMMs. The Kit inhibitor imatinib could benefit metastatic OMM patients with c-Kit mutations.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19746